<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01810809</url>
  </required_header>
  <id_info>
    <org_study_id>0255/10</org_study_id>
    <nct_id>NCT01810809</nct_id>
  </id_info>
  <brief_title>Hip Viscosupplementation: What is the Best Dosage?</brief_title>
  <acronym>Hip VS</acronym>
  <official_title>Hip Viscosupplementation: What is the Best Dosage?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intraarticular injections have long been used to treat osteoarthritis. Viscosupplementation
      is a relatively new approach comprising the injection of hyaluronic acid into diarthrodial
      joints. The dosis regimen is well established for the knee joint, but there is still no
      consensus regarding the optimal dosage for hip viscosupplementation. Our objective is to
      determine the optimal dosis for hip viscosupplementation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intraarticular injections have long been used to treat osteoarthritis. Viscosupplementation
      is a relatively new approach comprising the injection of hyaluronic acid into diarthrodial
      joints. Any osteoarthritic joint is eligible to this treatment modality, but the great
      majority of studies are for knee viscosupplementation. The dosis regimen is well established
      for the knee joint, but there is still no consensus regarding the optimal dosage for hip
      viscosupplementation. We will prospectively enroll 80 patients with hip osteoarthritis and
      will randomize them into four groups: Group zero will receive joint lavage with saline
      injection. Group 1 will receive joint lavage with saline injection and 2 ml of Hylan GF-20 (1
      ampoule of Synvisc Classic®). Group 2 will receive joint lavage with saline injection and 4
      ml of Hylan GF-20 (2 ampoules of Synvisc Classic®). Group 3 will receive joint lavage with
      saline injection and 6 ml of Hylan GF-20 (3 ampoules of Synvisc Classic®). The Visual
      Analogic Scale of Pain (VAS), the Western Ontario and McMaster Universities Index (WOMAC®),
      and Lequesne questionnaires were completed at baseline and at Weeks 1, 4, 12, and 24. Our
      objective is to determine the optimal dosis for hip viscosupplementation
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC</measure>
    <time_frame>6 months</time_frame>
    <description>Pain and function assessment with WOMAC questionaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS</measure>
    <time_frame>6 months</time_frame>
    <description>Pain assessment with Visual Analogic Scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lequesne</measure>
    <time_frame>6 months</time_frame>
    <description>Pain and function assessment with Lequesne questionaire</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Articular Lavage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients from Group Zero will receive articular lavage with saline injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients from Group 1 will receive articular lavage with saline injection and viscosupplementation with 2ml (1 ampoule) of Hylan GF-20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients from Group 2 will receive articular lavage with saline injection and viscosupplementation with 4ml (2 ampoules) of Hylan GF-20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients from Group 3 will receive articular lavage with saline injection and viscosupplementation with 6ml (3 ampoules) of Hylan GF-20</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>articular lavage with saline injection</intervention_name>
    <description>Patients will receive articular lavage with saline injection</description>
    <arm_group_label>Articular Lavage</arm_group_label>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 ampoule of Hylan GF-20</intervention_name>
    <description>Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>1 ampole of Synvisc Classic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 ampoules of Hylan GF-20</intervention_name>
    <description>Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>2 ampoles of Synvisc Classic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 ampoules of Hylan GF-20</intervention_name>
    <description>Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>3 ampoules of Synvisc Classic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Met the American College of Rheumatology criteria for hip osteoarthritis

          -  No hip intraarticular injections in the last 6 months

        Exclusion Criteria:

        - Severe reaction to the procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo C de Campos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FMUSP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gustavo C de Campos, MD</last_name>
    <phone>+551983318000</phone>
    <email>gustavoccampos@terra.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcia U Rezende, PhD</last_name>
    <phone>+5511981226282</phone>
    <email>murezende@uol.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto de Ortopedia e Traumatologia HC-FMUSP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05410-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valquiria</last_name>
      <phone>+551126616888</phone>
    </contact>
    <investigator>
      <last_name>Marcia U Rezende, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2013</study_first_submitted>
  <study_first_submitted_qc>March 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2013</study_first_posted>
  <last_update_submitted>September 10, 2013</last_update_submitted>
  <last_update_submitted_qc>September 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Hip</keyword>
  <keyword>Viscosupplementation</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

